Table 1.
Baseline characteristics of D-Vitaal study participants.
| Placebo N = 65 |
Vitamin D3 N = 66 |
Placebo N = 30 ** |
Vitamin D3 N = 40 ** |
|
|---|---|---|---|---|
| Female sex (%) | 44 (56%) | 45 (58%) | 14 (47%) | 23 (58%) |
| Age (year) | 67.7 ± 5.1 | 68.5 ± 5.3 | 67.1 ± 4.9 | 68.5 ± 5.1 |
| Baseline summer season | 38 (59%) | 37 (56%) | 16 (53%) | 18 (45%) |
| Plasma 25(OH)D (nmol/L) | 43.3 ± 14.5 | 45.1 ± 15.3 | 40.4 ± 14.5 | 42.9 ± 15.2 |
| Plasma dp-ucMGP (pmol/L) | 735 ± 638 | 651 ± 462 | 596 ± 355 | 504 ± 171 |
| Vitamin K antagonist use | 9 (14%) | 7 (11%) | - | - |
| Multivitamin use | 27 (44%) | 23 (35%) | - | - |
| Vitamin D use * | 1 (2%) | 3 (5%) | - | - |
| Compliance > 80% | 59 (91%) | 62 (94%) | 27 (90%) | 38 (95%) |
Values represent number and percentages or mean and standard deviation. * Vitamin D use by participant max 400 IU vitamin D3. ** excluding vitamin K antagonist users and multivitamin use.